Hanneke van der Wijngaart
Overview
Explore the profile of Hanneke van der Wijngaart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeverijn L, Geurts B, Battaglia T, van Berge Henegouwen J, de Wit G, Hoes L, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4339-4351.
PMID: 39024037
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches....
2.
van Berge Henegouwen J, Zeverijn L, Geurts B, Hoes L, van der Wijngaart H, van der Noort V, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3937-3943.
PMID: 38926908
Purpose: Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening...
3.
Geurts B, Zeverijn L, van Berge Henegouwen J, van der Wijngaart H, Hoes L, de Wit G, et al.
J Pathol
. 2024 May;
263(3):288-299.
PMID: 38747304
In the Drug Rediscovery Protocol (DRUP), patients with cancer are treated based on their tumor molecular profile with approved targeted and immunotherapies outside the labeled indication. Importantly, patients undergo a...
4.
Geurts B, Zeverijn L, Leek L, van Berge Henegouwen J, Hoes L, van der Wijngaart H, et al.
Clin Cancer Res
. 2024 Apr;
30(17):3735-3746.
PMID: 38630551
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients...
5.
van der Wijngaart H, Beekhof R, Knol J, Henneman A, de Goeij-de Haas R, Piersma S, et al.
Clin Proteomics
. 2023 Nov;
20(1):49.
PMID: 37940875
The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify...
6.
Zeverijn L, Looze E, Thavaneswaran S, van Berge Henegouwen J, Simes R, Hoes L, et al.
Int J Cancer
. 2023 Jul;
153(7):1413-1422.
PMID: 37424386
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical...
7.
van der Wijngaart H, Jagga S, Dekker H, de Goeij R, Piersma S, Pham T, et al.
Cancer Med
. 2023 Mar;
12(9):10979-10989.
PMID: 36916528
Purpose: In precision oncology, tumor molecular profiles guide selection of therapy. Standardized snap freezing of tissue biospecimens is necessary to ensure reproducible, high-quality samples that preserve tumor biology for adequate...
8.
Geurts B, Battaglia T, van Berge Henegouwen J, Zeverijn L, de Wit G, Hoes L, et al.
BMC Cancer
. 2023 Mar;
23(1):205.
PMID: 36870947
Background: In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the...
9.
Hoes L, van Berge Henegouwen J, van der Wijngaart H, Zeverijn L, van der Velden D, van de Haar J, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1402-1411.
PMID: 35046062
Purpose: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We...
10.
van der Wijngaart H, Hoes L, van Berge Henegouwen J, van der Velden D, Zeverijn L, Roepman P, et al.
Clin Cancer Res
. 2021 Sep;
27(22):6106-6114.
PMID: 34475104
Purpose: To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with mutations, regardless of histologic tumor type. Patients And Methods: Patients with treatment-refractory mutated cancer...